[Final height in 69 patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency].
David
M
M
Service de pédiatrie, centre hospitalier Lyon Sud, Lyon, France.
Sempé
M
M
Blanc
M
M
Nicolino
M
M
Forest
M G
MG
Morel
Y
Y
D000312:Adrenal Hyperplasia, Congenital / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D000365:Age Determination by Skeleton; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001827:Body Height / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D003900:Desoxycorticosterone / Q000627:therapeutic use*; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D012189:Retrospective Studies
D000893:Anti-Inflammatory Agents; D003900:Desoxycorticosterone; D017258:Medroxyprogesterone Acetate
Taille définitive chez 69 sujets atteints d'hyperplasie congénitale des surrénales par déficit en 21-hydroxylase.